Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with AOC

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

The biotech delivers some highly encouraging news on the clinical front.

Why Clovis Oncology Zoomed 30% Higher Today

Astra Space

FuboTV

Short Squeeze Penny Stocks To Watch The post Penny Stocks To Buy: 3 Short Squeeze Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 3 Short Squeeze Stocks To Watch Right Now

Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is rising higher on Monday following the release of results from a Phase 3 clinical trial. That trail covers Rubraca as a monotherapy for the treatment of ovarian cancer.

Why Is Clovis Oncology (CLVS) Stock Up 11% Today?

Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

The biotech's Q2 financial results are concerning investors today.

Why Clovis Oncology Stock Is Sinking Today

Clovis Oncology (NASDAQ: CLVS ) stock is down more than 10% today after posting its second-quarter financial results. The biopharmaceutical company missed on revenue and profits, leading the way for today's selloff.

Why Is Clovis Oncology (CLVS) Stock Down 10% Today?

Clovis Oncology, Inc. (NASDAQ:CLVS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR Patrick Mahaffy - Co-Founder, CEO, President & Executive Director Lindsey Rolfe - EVP, Clinical Development & Pharmacovigilance and Chief Medical Officer Daniel Muehl - EVP & CFO Conference Call Participants Operator Good morning. My name is Samantha, and I will be your conference operator today.

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2022 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2022, and provided an update on the Company's clinical development programs and regulatory and commercial outlook. “We achieved a key milestone in the second quarter, with the presentations of the first clinical data from the LuMIERE trial of FAP-2286 and from the ongoing imaging-only investigator-initiated study. In addition to seeing the first evidence of safety and c

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--First paragraph, second sentence of release should read: Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis' results and business outlook in greater detail. (instead of Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail.). The updated release reads: CLOVIS ONCOLOGY TO ANNOUNCE SECOND QUARTER 2022 FINANC

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcas

Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

Investors were cheered by news of a freshly signed supply deal.

Why Clovis Oncology Stock Trounced the Market Today

CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.

Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Clovis Oncology (NASDAQ: CLVS) signed a supply agreement for therapeutic radioisotope actinium-225 (Ac-225).

NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)

After a massive surge in its share price recently, Clovis Oncology has started to reverse course.

Why Clovis Oncology Stock Went Into Retreat Mode This Week

Clovis Oncology has recently been on a winning streak of clinical data and corporate updates. As a result, the share price has rocketed off its 52-week lows. The company's theranostic FAP was able to show some efficacy in its Phase I trial. This validated the company's efforts to develop these programs.

Clovis Oncology: Managing A Winning Position After Recent Company Updates

Biotech stocks are back in favor as some risk-on activity permeates the broader market. Clovis Oncology (CLVS) shares spiked from under 50 cents to above $3 recently as news about its key drugs stirs up bullish fervor.

Clovis Oncology: Shares Pop And Drop Around FDA News (Technical Analysis)

Clovis Oncology is skyrocketing after being flagged as a top gamma squeeze candidate. Here's why investors should be watching CLVS stock.

Is Clovis Oncology (CLVS) Stock the Next Big Squeeze?

Shareholders didn't give short-sellers what they wanted.

Why Clovis Oncology Stock Is Crushing It Today

Clovis' (CLVS) shareholders decided to reject a proposal for a reverse split of CLVS stock. Clovis' shares appear to be rising on the news.

News for Clovis Oncology Stock (CLVS)